Bank of New York Mellon’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-11,198
| Closed | -$46.4K | – | 4275 |
|
|
2023
Q4 | $46.4K | Sell |
11,198
-25,521
| -70% | -$106K | ﹤0.01% | 4156 |
|
|
2023
Q3 | $110K | Sell |
36,719
-42,709
| -54% | -$128K | ﹤0.01% | 4058 |
|
|
2023
Q2 | $195K | Sell |
79,428
-74,075
| -48% | -$182K | ﹤0.01% | 3973 |
|
|
2023
Q1 | $347K | Sell |
153,503
-32,659
| -18% | -$73.8K | ﹤0.01% | 3678 |
|
|
2022
Q4 | $650K | Sell |
186,162
-28,714
| -13% | -$100K | ﹤0.01% | 3413 |
|
|
2022
Q3 | $7.96M | Sell |
214,876
-27,143
| -11% | -$1M | ﹤0.01% | 2034 |
|
|
2022
Q2 | $4.6M | Buy |
242,019
+5,006
| +2% | +$95.1K | ﹤0.01% | 2363 |
|
|
2022
Q1 | $6.4M | Buy |
237,013
+24,151
| +11% | +$652K | ﹤0.01% | 2291 |
|
|
2021
Q4 | $4.8M | Buy |
212,862
+14,928
| +8% | +$336K | ﹤0.01% | 2483 |
|
|
2021
Q3 | $5.19M | Sell |
197,934
-1,190
| -0.6% | -$31.2K | ﹤0.01% | 2462 |
|
|
2021
Q2 | $6.37M | Buy |
199,124
+9,580
| +5% | +$307K | ﹤0.01% | 2375 |
|
|
2021
Q1 | $6.67M | Buy |
189,544
+24,425
| +15% | +$860K | ﹤0.01% | 2305 |
|
|
2020
Q4 | $5.3M | Sell |
165,119
-12,380
| -7% | -$397K | ﹤0.01% | 2331 |
|
|
2020
Q3 | $6.68M | Buy |
177,499
+45,068
| +34% | +$1.7M | ﹤0.01% | 2070 |
|
|
2020
Q2 | $5.93M | Buy |
132,431
+34,287
| +35% | +$1.53M | ﹤0.01% | 2129 |
|
|
2020
Q1 | $3.35M | Sell |
98,144
-4,470
| -4% | -$152K | ﹤0.01% | 2282 |
|
|
2019
Q4 | $4M | Buy |
+102,614
| New | +$4M | ﹤0.01% | 2441 |
|